Developer docs
API playgroundTry for free, no card

Search company profiles

Actinium Pharmaceuticals

Full company profile

uuid000533t

Namestring
Actinium Pharmaceuticals
Legal namestring
Actinium Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Actinium Pharmaceuticals, Inc. is a New York-based, clinical-stage biopharmaceutical company (NYSE American: ATNM) developing targeted alpha-particle radiotherapies that conjugate Actinium-225 (Ac-225) to monoclonal antibodies for the treatment of cancer. Its pipeline comprises three core programs: ATNM-400, a first-in-class Ac-225 antibody radioconjugate aimed at multiple solid tumor indications including metastatic castration-resistant prostate cancer (including PSMA-negative and ARPI-resistant disease), non-small cell lung cancer (EGFR- and KRAS-mutated), and breast cancer (hormone receptor-positive, HER2-positive, and triple-negative); Actimab-A (lintuzumab-Ac225), an Ac-225-labeled anti-CD33 antibody in development for acute myeloid leukemia that demonstrated an 83% overall response rate with 75% MRD-negativity in a Phase 1 relapsed/refractory trial; and Iomab-ACT, a CD45-targeted Ac-225 conditioning agent designed to enable bone marrow transplant and gene-edited cell therapy applications. The company has built a proprietary radiochemistry capability around chelator-to-antibody ratio (CAR) optimization that reduces off-target hepatic and splenic uptake while preserving tumor targeting, and it is protected by approximately 250 issued and pending patents and applications across the United States, Canada, Japan, Europe, and China, with key composition-of-matter and method claims extending to 2038-2039.

The company is pre-commercial with no disclosed product revenue or pricing; its go-to-market model is built around NCI-sponsored clinical trials and development partnerships (e.g., an NCI-led Actimab-A combination study in newly diagnosed AML advancing toward a Phase 2/3 registrational study under FDA alignment). Customer-facing activity is focused on oncology conference presentations, peer-reviewed publications, and investor relations rather than commercial distribution. Financially, the company is loss-making with net losses in five consecutive fiscal years through December 31, 2025, stockholders' equity of approximately $2.3 million versus a $4.0 million NYSE American minimum (triggering a delisting notice in May 2026 with a compliance plan due by June 26, 2026 and a cure deadline of November 27, 2027), a market capitalization of approximately $30.6 million, and a current ratio of 6.2 reflecting a liquid but equity-thin balance sheet.

Short descriptiontext

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapies using Actinium-225-conjugated antibodies to treat hematologic malignancies and solid tumors including prostate, lung, and breast cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
targeted alpha therapy, antibody radioconjugates, radiopharmaceutical drug development, cancer radiotherapy pipeline, clinical stage biopharmaceuticals
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Targeted Radiopharmaceuticals
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Actinium Pharmaceuticals develops targeted alpha-particle radiotherapies using Actinium-225 (Ac-225) conjugated to antibodies to treat cancer. Its pipeline includes ATNM-400 for solid tumors (prostate, lung, breast), Actimab-A for acute myeloid leukemia, and Iomab-ACT for conditioning prior to gene-edited cell therapies. The company leverages proprietary radiochemistry including chelator-to-antibody ratio (CAR) optimization to improve therapeutic index. All assets are currently in preclinical or early clinical development with no commercialized products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 94% tumor growth inhibition in ARPI-resistant prostate cancer models vs 32% for apalutamide and 5% for darolutamide
+3 more records
Product overview1 text field

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies using Actinium-225 (Ac-225) alpha-particle radiation. The company's pipeline consists of three key programs: ATNM-400, a first-in-class Ac-225 antibody radioconjugate for solid tumors including prostate, lung, and breast cancers; Actimab-A (lintuzumab-Ac225), an Ac-225 labeled antibody for acute myeloid leukemia; and Iomab-ACT, a CD45 conditioning agent for gene-edited cell-based therapies. The company leverages proprietary radiochemistry capabilities including chelator-to-antibody ratio (CAR) optimization to improve therapeutic index across its radiopharmaceutical programs.

Product and service4 records
1ATNM-400
CategoryDrug Candidate
Description

First-in-class Actinium-225 antibody radioconjugate for solid tumors; demonstrates efficacy across prostate cancer (PSMA-high, PSMA-low, and PSMA-negative; ARPI-resistant), non-small cell lung cancer (EGFR-mutant and KRAS-mutated), and breast cancer (hormone receptor-positive, HER2-positive, and triple-negative) preclinical models, outperforming approved therapies including enzalutamide, apalutamide, darolutamide, osimertinib, trastuzumab deruxtecan, and 177Lu-PSMA-617 in preclinical studies.

2Actimab-A (lintuzumab-Ac225)
CategoryDrug Candidate
Description

Actinium-225 labeled antibody therapy for acute myeloid leukemia (AML); demonstrates mutation-agnostic anti-leukemic activity via transcriptional reprogramming; Phase 1 trial achieved 83% overall response rate with 75% MRD-negativity in relapsed/refractory AML in combination with CLAG-M chemotherapy; being advanced into a Phase 2/3 registrational study with FDA alignment and is the subject of an NCI-sponsored combination trial with venetoclax and ASTX-727 in newly diagnosed AML.

3Iomab-ACT
CategoryDrug Candidate
Description

CD45-targeted Actinium-225 conditioning agent for gene-edited cell-based therapies; provides targeted bone marrow conditioning prior to gene therapy procedures and bone marrow transplant; patent term extends to October 2038 under Canadian patent protection.

4225Ac Radioconjugate Platform
CategoryTechnology Platform
Description

Proprietary Actinium-225 (Ac-225) alpha-particle radiochemistry platform underpinning the company's radiopharmaceutical pipeline; incorporates chelator-to-antibody ratio (CAR) optimization technology that improves tumor targeting, reduces off-target uptake in liver and spleen, and supports an extended therapeutic window across the pipeline assets.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Dr. Steffen Heeger, newly appointed CMO of Actinium Pharmaceuticals, previously served as CMO of Full-Life Technologies where he advanced anti-PSMA radioconjugate programs into clinical development within two years, securing IND clearance and fast-track designation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

NCI-sponsored clinical trial combining Actimab-A with venetoclax and ASTX-727 for newly diagnosed AML patients. NCI collaboration advancing Actimab-A toward a Phase 2/3 registrational study for relapsed/refractory AML under FDA alignment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns Pluvicto (177Lu-PSMA-617), the only commercially approved PSMA-directed radioligand therapy. Comparable because it operates in the same targeted radiotherapy oncology space Actinium targets with its Ac-225 platform, though Novartis is a diversified large pharma and Pluvicto targets the PSMA-positive patient population that ATNM-400 is designed to complement or bypass.

TypeDirect peer
Description

Radiopharmaceutical company with commercial PSMA imaging agents (PYLARIFY) and an expanding radiotherapeutic pipeline. Comparable as a US-listed, focused radiopharma that serves the same prostate cancer imaging/treatment workflow where Actinium's ATNM-400 aims to treat post-imaging.

TypeDirect peer
Description

Commercial-stage radiopharma with Illuccix (PSMA imaging) and an early therapeutic pipeline including TLX591 (177Lu-PSMA antibody). Comparable as a clinical-to-commercial radiopharma operating in the same PSMA-prostate cancer category and pursuing adjacent radioligand therapy development.

TypeBroad incumbent
Description

Markets Xofigo (223Ra-dichloride), the first commercially approved alpha-emitting radiopharmaceutical for prostate cancer bone metastases. Comparable as a large pharma with a commercial alpha-emitter franchise that establishes the regulatory and commercial template Actinium would need to follow.

TypeBroad incumbent
Description

Acquired POINT Biopharma in 2023 to gain a PSMA-targeted radioligand therapy (POINT's PNT2002/177Lu-PSMA-I&T) plus a manufacturing infrastructure footprint. Comparable because it is now a direct competitor in PSMA radioligand therapy with the resources to scale that Actinium lacks.

TypeBroad incumbent
Description

Acquired Fusion Pharmaceuticals in 2024 specifically for its targeted alpha therapy (Ac-225-based) platform — directly overlapping with Actinium's core technology. Comparable because Fusion is the closest direct competitor in Ac-225 radiochemistry and is now backed by big-pharma resources.

7Bristol Myers Squibb (RayzeBio)
TypeBroad incumbent
Description

Acquired RayzeBio in 2024 for its actinium-225-based targeted radiopharmaceutical pipeline. Comparable as another big-pharma entrant in the Ac-225 space, validating the platform thesis while raising the competitive bar through resources and pipeline breadth.

TypeEmerging player
Description

Clinical-stage company developing phospholipid drug conjugate-targeted radiopharmaceuticals (including Iopofosine I-131) for hematologic and solid tumors. Comparable as a small-cap US radiopharma with similar clinical-stage scale, capital-constraints profile, and reliance on partnership or M&A to advance.

TypeOthers
Description

Specializes in medical radioisotope manufacturing and radiopharmaceutical development, including targeted radionuclide therapies using Lu-177 and other emitters. Comparable as a supplier/infrastructure participant in the same targeted radionuclide therapy supply chain that Actinium depends on for Ac-225 production and chelation chemistry.

TypeEmerging player
Description

Clinical-stage biotech developing DARPin-based targeted radioligand therapies, including programs against HER2 and other oncology targets. Comparable as a small-cap company engineering alternative scaffold (DARPin vs. antibody) radioconjugates that could compete with Actinium's antibody-Ac-225 constructs in similar tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actinium Pharmaceuticals

Targeted Radiopharmaceuticalsactiniumpharmaceuticals.com

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapies using Actinium-225-conjugated antibodies to treat hematologic malignancies and solid tumors including prostate, lung, and breast cancers.

What Actinium Pharmaceuticals does

Actinium Pharmaceuticals, Inc. is a New York-based, clinical-stage biopharmaceutical company (NYSE American: ATNM) developing targeted alpha-particle radiotherapies that conjugate Actinium-225 (Ac-225) to monoclonal antibodies for the treatment of cancer. Its pipeline comprises three core programs: ATNM-400, a first-in-class Ac-225 antibody radioconjugate aimed at multiple solid tumor indications including metastatic castration-resistant prostate cancer (including PSMA-negative and ARPI-resistant disease), non-small cell lung cancer (EGFR- and KRAS-mutated), and breast cancer (hormone receptor-positive, HER2-positive, and triple-negative); Actimab-A (lintuzumab-Ac225), an Ac-225-labeled anti-CD33 antibody in development for acute myeloid leukemia that demonstrated an 83% overall response rate with 75% MRD-negativity in a Phase 1 relapsed/refractory trial; and Iomab-ACT, a CD45-targeted Ac-225 conditioning agent designed to enable bone marrow transplant and gene-edited cell therapy applications. The company has built a proprietary radiochemistry capability around chelator-to-antibody ratio (CAR) optimization that reduces off-target hepatic and splenic uptake while preserving tumor targeting, and it is protected by approximately 250 issued and pending patents and applications across the United States, Canada, Japan, Europe, and China, with key composition-of-matter and method claims extending to 2038-2039.

The company is pre-commercial with no disclosed product revenue or pricing; its go-to-market model is built around NCI-sponsored clinical trials and development partnerships (e.g., an NCI-led Actimab-A combination study in newly diagnosed AML advancing toward a Phase 2/3 registrational study under FDA alignment). Customer-facing activity is focused on oncology conference presentations, peer-reviewed publications, and investor relations rather than commercial distribution. Financially, the company is loss-making with net losses in five consecutive fiscal years through December 31, 2025, stockholders' equity of approximately $2.3 million versus a $4.0 million NYSE American minimum (triggering a delisting notice in May 2026 with a compliance plan due by June 26, 2026 and a cure deadline of November 27, 2027), a market capitalization of approximately $30.6 million, and a current ratio of 6.2 reflecting a liquid but equity-thin balance sheet.

Actinium Pharmaceuticals firmographics

Firmographics
Name
Actinium Pharmaceuticals
Legal name
Actinium Pharmaceuticals, Inc.
Website
https://actiniumpharmaceuticals.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapies using Actinium-225-conjugated antibodies to treat hematologic malignancies and solid tumors including prostate, lung, and breast cancers.
Ownership category
akta.pro rank

Actinium Pharmaceuticals industry classification

Industry
Product category
Targeted Radiopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted alpha therapy
  • Antibody radioconjugates
  • Radiopharmaceutical drug development
  • Cancer radiotherapy pipeline
  • Clinical stage biopharmaceuticals

Where Actinium Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Actinium Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels3 records

Actinium Pharmaceuticals product offering

Product offering

Core offering

Actinium Pharmaceuticals develops targeted alpha-particle radiotherapies using Actinium-225 (Ac-225) conjugated to antibodies to treat cancer. Its pipeline includes ATNM-400 for solid tumors (prostate, lung, breast), Actimab-A for acute myeloid leukemia, and Iomab-ACT for conditioning prior to gene-edited cell therapies. The company leverages proprietary radiochemistry including chelator-to-antibody ratio (CAR) optimization to improve therapeutic index. All assets are currently in preclinical or early clinical development with no commercialized products.

Product overview

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies using Actinium-225 (Ac-225) alpha-particle radiation. The company's pipeline consists of three key programs: ATNM-400, a first-in-class Ac-225 antibody radioconjugate for solid tumors including prostate, lung, and breast cancers; Actimab-A (lintuzumab-Ac225), an Ac-225 labeled antibody for acute myeloid leukemia; and Iomab-ACT, a CD45 conditioning agent for gene-edited cell-based therapies. The company leverages proprietary radiochemistry capabilities including chelator-to-antibody ratio (CAR) optimization to improve therapeutic index across its radiopharmaceutical programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATNM-400 First-in-class Actinium-225 antibody radioconjugate for solid tumors; demonstrates efficacy across prostate cancer (PSMA-high, PSMA-low, and PSMA-negative; ARPI-resistant), non-small cell lung cancer (EGFR-mutant and KRAS-mutated), and breast cancer (hormone receptor-positive, HER2-positive, and triple-negative) preclinical models, outperforming approved therapies including enzalutamide, apalutamide, darolutamide, osimertinib, trastuzumab deruxtecan, and 177Lu-PSMA-617 in preclinical studies.
  • Actimab-A (lintuzumab-Ac225) Actinium-225 labeled antibody therapy for acute myeloid leukemia (AML); demonstrates mutation-agnostic anti-leukemic activity via transcriptional reprogramming; Phase 1 trial achieved 83% overall response rate with 75% MRD-negativity in relapsed/refractory AML in combination with CLAG-M chemotherapy; being advanced into a Phase 2/3 registrational study with FDA alignment and is the subject of an NCI-sponsored combination trial with venetoclax and ASTX-727 in newly diagnosed AML.
  • Iomab-ACT CD45-targeted Actinium-225 conditioning agent for gene-edited cell-based therapies; provides targeted bone marrow conditioning prior to gene therapy procedures and bone marrow transplant; patent term extends to October 2038 under Canadian patent protection.
  • 225Ac Radioconjugate Platform Proprietary Actinium-225 (Ac-225) alpha-particle radiochemistry platform underpinning the company's radiopharmaceutical pipeline; incorporates chelator-to-antibody ratio (CAR) optimization technology that improves tumor targeting, reduces off-target uptake in liver and spleen, and supports an extended therapeutic window across the pipeline assets.

Quantifiable outcome

  • 94% tumor growth inhibition in ARPI-resistant prostate cancer models vs 32% for apalutamide and 5% for darolutamide
  • +3 more outcomes

Companies that use Actinium Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles3 records

Actinium Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Actinium Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Full-Life TechnologiesminorStrategic or Co-development Partner · 1 June 2026Dr. Steffen Heeger, newly appointed CMO of Actinium Pharmaceuticals, previously served as CMO of Full-Life Technologies where he advanced anti-PSMA radioconjugate programs into clinical development within two years, securing IND clearance and fast-track designation.
  • National Cancer Institute (NCI)coreStrategic or Co-development Partner · 22 April 2026NCI-sponsored clinical trial combining Actimab-A with venetoclax and ASTX-727 for newly diagnosed AML patients. NCI collaboration advancing Actimab-A toward a Phase 2/3 registrational study for relapsed/refractory AML under FDA alignment.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Actinium Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Owns Pluvicto (177Lu-PSMA-617), the only commercially approved PSMA-directed radioligand therapy. Comparable because it operates in the same targeted radiotherapy oncology space Actinium targets with its Ac-225 platform, though Novartis is a diversified large pharma and Pluvicto targets the PSMA-positive patient population that ATNM-400 is designed to complement or bypass.
  • Bayer: Markets Xofigo (223Ra-dichloride), the first commercially approved alpha-emitting radiopharmaceutical for prostate cancer bone metastases. Comparable as a large pharma with a commercial alpha-emitter franchise that establishes the regulatory and commercial template Actinium would need to follow.
  • Eli Lilly (POINT Biopharma): Acquired POINT Biopharma in 2023 to gain a PSMA-targeted radioligand therapy (POINT's PNT2002/177Lu-PSMA-I&T) plus a manufacturing infrastructure footprint. Comparable because it is now a direct competitor in PSMA radioligand therapy with the resources to scale that Actinium lacks.
  • AstraZeneca (Fusion Pharmaceuticals): Acquired Fusion Pharmaceuticals in 2024 specifically for its targeted alpha therapy (Ac-225-based) platform — directly overlapping with Actinium's core technology. Comparable because Fusion is the closest direct competitor in Ac-225 radiochemistry and is now backed by big-pharma resources.
  • Bristol Myers Squibb (RayzeBio): Acquired RayzeBio in 2024 for its actinium-225-based targeted radiopharmaceutical pipeline. Comparable as another big-pharma entrant in the Ac-225 space, validating the platform thesis while raising the competitive bar through resources and pipeline breadth.

Direct peers

  • Lantheus Holdings: Radiopharmaceutical company with commercial PSMA imaging agents (PYLARIFY) and an expanding radiotherapeutic pipeline. Comparable as a US-listed, focused radiopharma that serves the same prostate cancer imaging/treatment workflow where Actinium's ATNM-400 aims to treat post-imaging.
  • Telix Pharmaceuticals: Commercial-stage radiopharma with Illuccix (PSMA imaging) and an early therapeutic pipeline including TLX591 (177Lu-PSMA antibody). Comparable as a clinical-to-commercial radiopharma operating in the same PSMA-prostate cancer category and pursuing adjacent radioligand therapy development.

Emerging players

  • Cellectar Biosciences: Clinical-stage company developing phospholipid drug conjugate-targeted radiopharmaceuticals (including Iopofosine I-131) for hematologic and solid tumors. Comparable as a small-cap US radiopharma with similar clinical-stage scale, capital-constraints profile, and reliance on partnership or M&A to advance.
  • Molecular Partners: Clinical-stage biotech developing DARPin-based targeted radioligand therapies, including programs against HER2 and other oncology targets. Comparable as a small-cap company engineering alternative scaffold (DARPin vs. antibody) radioconjugates that could compete with Actinium's antibody-Ac-225 constructs in similar tumor indications.

Others

  • ITM Isotope Technologies Munich: Specializes in medical radioisotope manufacturing and radiopharmaceutical development, including targeted radionuclide therapies using Lu-177 and other emitters. Comparable as a supplier/infrastructure participant in the same targeted radionuclide therapy supply chain that Actinium depends on for Ac-225 production and chelation chemistry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Actinium Pharmaceuticals social profiles

Digital presence

Actinium Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actinium Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Actinium Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actinium Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actinium Pharmaceuticals

What does Actinium Pharmaceuticals do?

Actinium Pharmaceuticals develops targeted alpha-particle radiotherapies using Actinium-225 (Ac-225) conjugated to antibodies to treat cancer. Its pipeline includes ATNM-400 for solid tumors (prostate, lung, breast), Actimab-A for acute myeloid leukemia, and Iomab-ACT for conditioning prior to gene-edited cell therapies. The company leverages proprietary radiochemistry including chelator-to-antibody ratio (CAR) optimization to improve therapeutic index. All assets are currently in preclinical or early clinical development with no commercialized products.

Is Actinium Pharmaceuticals a public or private company?

Actinium Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Actinium Pharmaceuticals founded?

Actinium Pharmaceuticals was founded in 2012. It employs 11 to 50 people.

Where is Actinium Pharmaceuticals based?

Actinium Pharmaceuticals is headquartered in New York, United States, in the North America region.

Who are Actinium Pharmaceuticals's main competitors?

Broad incumbents on record are Novartis, Bayer, Eli Lilly (POINT Biopharma), AstraZeneca (Fusion Pharmaceuticals) and Bristol Myers Squibb (RayzeBio). Direct peers are Lantheus Holdings and Telix Pharmaceuticals. Emerging players are Cellectar Biosciences and Molecular Partners. ITM Isotope Technologies Munich is listed as an others.

Does Actinium Pharmaceuticals have an API?

No public API is recorded for Actinium Pharmaceuticals.

What industry is Actinium Pharmaceuticals in?

Actinium Pharmaceuticals's product category is Targeted Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireActinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha RadiotherapyActinium Pharmaceuticals will host a KOL webinar on December 1, 2026, to discuss ATNM-400, its HER3-targeted alpha radiotherapy for metastatic castration-resistant prostate cancer. The webinar will review Phase 1 data from HERACT-PRO-1, including tumor uptake and retention through Day 7 with no dose-limiting toxicities, and detail the RADIANZ imaging study for pan-tumor potential.Stock TitanActinium Pharmaceuticals sets Dec. 1 ATNM-400 webinarActinium Pharmaceuticals will host a KOL webinar on December 1, 2026, to discuss ATNM-400, its HER3-targeted alpha radiotherapy for prostate cancer. The webinar will review Phase 1 data from the HERACT-PRO-1 trial, including initial findings from three patients and ongoing dose escalation to 1.5 µCi/kg. It will also cover the RADIANZ imaging study and preclinical activity across solid tumors.Investing.comActinium begins enrolling patients in RADIANZ imaging trialActinium Pharmaceuticals began enrolling patients in its RADIANZ imaging trial for ATNM-400, an Actinium-225 antibody radioconjugate targeting HER3. The trial will use Zirconium-89-barecetamab PET imaging to guide dosing in solid tumors beyond prostate cancer. The company presented preclinical data in lung, colorectal, and ovarian cancer models.Investing.comActinium Pharmaceuticals forms scientific advisory boardActinium Pharmaceuticals formed a scientific advisory board of five clinicians and scientists to guide its radioconjugate pipeline, including ATNM-400, a HER3-targeted alpha radiotherapy in a Phase 1 study for metastatic castration-resistant prostate cancer. The board will support clinical development strategies, trial design, and patient selection across solid tumor and hematologic malignancy programs.PR NewswireActinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical DevelopmentActinium Pharmaceuticals announced the formation of a Scientific Advisory Board with five experts in oncology and radiopharmaceutical development. The board will guide its radioconjugate pipeline, including ATNM-400, a HER3-targeted alpha radiotherapy in a first-in-human Phase 1 study for metastatic castration-resistant prostate cancer.Stock TitanActinium Pharmaceuticals Forms Scientific Advisory BoardActinium Pharmaceuticals formed a five-member Scientific Advisory Board to guide its scientific and clinical development programs. The board features leading experts in oncology and radiopharmaceutical development.The future of tradingActinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026Actinium Pharmaceuticals presented three Iomab-ACT clinical abstracts at ASH 2026, including Memorial Sloan Kettering findings on immune-cell depletion before CAR T-cell therapy. A Phase 1b/2 trial evaluates Iomab-ACT conditioning before commercial CD19-directed CAR T-cell therapy, and preliminary sickle cell disease findings explore chemotherapy-free conditioning for donor engraftment.Stock TitanActinium ATNM-400 abstract accepted for SABCS 2026Actinium Pharmaceuticals announced acceptance of an ATNM-400 abstract for presentation at SABCS 2026, highlighting activity across therapy-resistant breast cancer models. The abstract will be presented at the 2026 San Antonio Breast Cancer Symposium.Investing.comActinium begins phase 1 trial of HER3-targeted cancer therapyActinium Pharmaceuticals will present its first-in-human Phase 1 study of ATNM-400, a HER3-targeted radioconjugate, at the European Society for Medical Oncology Congress in Madrid in October 2026. The study enrolls patients with metastatic castration-resistant prostate cancer and evaluates safety, dosimetry, and antitumor activity. The company aims to establish a recommended Phase 2 dose.MoomooActinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026Actinium Pharmaceuticals will present its first-in-human Phase 1 study of ATNM-400, a HER3-targeted alpha radiotherapy, at ESMO 2026 in Madrid. The study evaluates safety and tolerability in metastatic castration-resistant prostate cancer, including patients with PSMA-positive, low, or negative disease. Results aim to establish a recommended Phase 2 dose and support expansion into other solid tumors.